Webinar for Referring DVMs

W H A T   Y O U   WI L L   L E A R N

How Immunotherapy Can Make A Difference For Your Patients

As a family veterinarian, you’re most often the first encounter when a dog is diagnosed with cancer. Arm yourself with the latest information on the treatment options available to pet owners today.

The American Cancer Society website defines Immunotherapy as treatment that uses certain parts of a person’s immune system to fight diseases such as cancer. Immunotherapies that have achieved considerable success in the human health arena include checkpoint inhibitors and adoptive cell therapies such as chimeric antigen receptor (CAR) T cell therapies and TIL (tumor infiltrating lymphocytes). These are finally becoming available in veterinary medicine. In this program we will discuss the history and background of immunotherapy development, learn how to identify and distinguish between current cancer immunotherapy technologies, and discuss the conduct of the ELIAS Cancer Immunotherapy (ECI®) adoptive cell therapy protocol.

Learning Objectives:

  1. Demonstrate a basic understanding of the history and background of Immunotherapy Development for the Treatment of Cancer
  2. Identify and distinguish between cancer vaccines and adoptive cell therapies
  3. Understand the ELIAS Cancer Immunotherapy Protocol (ECI®)

Register for an Upcoming Session

Thursday
December 5, 2024

8:00 PM Central

Wednesday
December 18, 2024

6:00 PM Central

What Vets Are Saying About ECI®

“I really think that there is strong evidence that the ELIAS procedure benefited these dogs, substantially
and on average, based on that median survival. I will also point out that every single piece of the ELIAS
immunotherapy process is extremely well supported in the scientific literature across multiple species.”

Jeffrey Bryan, DVM, DACVIM (Oncology), University of Missouri

“There’s going to be a never-ending irreversible limitation of what autologous vaccine alone can do, which is why I’m attracted to the ECI product because of the activated T cell component. I don’t think that any of
these products or autologous vaccines that are out there today are that much different or are going to offer that much significant difference. Whereas I think ECI has some clear improvements and should
result in better results and better outcomes.”

K. Ann Jeglum, VMD, DACVIM (Oncology), Veterinary Oncology Services and Research Center

Make a Difference For Your Patients